Treatment of hepatitis C with interferon and ribavirin (Q33988146)

30 July 2017

1 reference

title

Treatment of hepatitis C with interferon and ribavirin (English)

1 reference

30 July 2017

1 reference

1 reference

S Pianko

1

1 reference

PubMed ID

10921409

30 July 2017

J G McHutchison

series ordinal

2

1 reference

30 July 2017

1 June 2000

1 reference

Journal of Gastroenterology and Hepatology

30 July 2017

1 reference

30 July 2017

15

1 reference

30 July 2017

581-586

1 reference

30 July 2017

6

1 reference

Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group

30 July 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02082.X

Non-A, non-B post-transfusion hepatitis. Looking back in the second decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02082.X

Treatment of chronic hepatitis C with interferon alfa-n3: a multicenter, randomized, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02082.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02082.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02082.X

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02082.X

A pilot study of ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02082.X

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02082.X

Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02082.X

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02082.X

Loss of serum HCV RNA at week 4 of interferon-alpha therapy is associated with more favorable long-term response in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02082.X

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02082.X

Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02082.X

Therapy of hepatitis C: re-treatment with alpha interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02082.X

Re-treatment of chronic hepatitis C with consensus interferon .

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02082.X

Therapy of viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02082.X

10.1046/J.1440-1746.2000.02082.X

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

10921409